EML4-ALK在非小细胞肺癌中的表达及检测  

Detection and Expression of the Transforming EML4-ALK Fusion Gene in Non-small Cell Lung Cancer

作　　者：梁宁[1] 单利[1] 王强[1] 

机构地区：[1]新疆医科大学附属肿瘤医院内一科,乌鲁木齐830011

出　　处：《医学综述》2011年第19期2907-2910,共4页Medical Recapitulate

摘　　要：非小细胞肺癌(NSCLC)为当今最常见的恶性肿瘤之一,近年来我国肺癌的发病率和病死率增长迅速,已居癌症相关死亡首位。分子靶向治疗已成为晚期NSCLC治疗的研究热点之一,靶向药物如何针对性地用于患者的治疗是关键。棘皮动物微管结合蛋白4(EML4)与间变淋巴瘤激酶(ALK)形成的融合基因主要表达于NSCLC中,这可能是与NSCLC表皮生长因子受体酪氨酸激酶抑制剂耐药相关的新靶点。Non-small cell lung cancer（NSCLC） is one of the most common malignant tumors with rapidly increasing incidence and mortality,and has become the top cancer related death cause.Molecular target therapy has become one of the hot research points for treatments for late NSCLC,and the pertinent application of the target drug is the key of the treatment.Fusion genes of echinoderm microtubule associated protein like 4（EML4） and anaplastic lymphoma kinase（ALK） are mainly expressed in NSCLC,which is probably the new target related to resistance of NSCLC epidermal growth factor receptor to tyrosine kinase inhibitors.

关 键 词：非小细胞肺癌 棘皮动物微管相关蛋白样4-间变淋巴瘤激酶 融合基因 

分 类 号：R73[医药卫生—肿瘤]